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Abstract
Background: Previously, TP53 codon 72 polymorphisms have been implicated as risk factors for
various cancers. A number of studies have conducted on the association of TP53 codon 72
polymorphisms with susceptibility to breast carcinoma and have yielded inconclusive results. The
aim of the present study was to derive a more precise estimation of the relationship.
Methods: We conducted a search in the Medline, EMBASE, OVID, Sciencedirect, and Chinese
National Knowledge Infrastructure (CNKI) without a language limitation, covering all papers
published up to Jan 2009. The associated literature was acquired through deliberate searching and
selected based on the established inclusion criteria for publications.
Results: A total of seventeen case-control studies, including 12226 cases and 10782 controls, met
the included criteria and thus were selected. Ultimately, the relevant data were extracted and
further analyzed using systematic meta-analyses. Overall, no associations of TP53 codon 72
polymorphisms with breast carcinoma were observed (for Arg/Arg vs Pro/Pro: OR = 1.20; 95%CI
= 0.96–1.50; for dominant model: OR = 1.12; 95%CI = 0.96–1.32; for recessive model: OR = 1.13;
95%CI = 0.98–1.31). In the subgroup analysis by ethnicity, statistically similar results were obtained
when the data were stratified as Asians, Caucasians and Africans.
Conclusion:  Collectively, the results of the present study suggest that TP53 codon 72
polymorphisms might not be a low-penetrant risk factor for developing breast carcinoma.
Backgrounds
Breast cancer is the second leading cause of cancer death
in women, exceeded only by lung cancer in the world [1].
It is believed that some epidemic factors such as Oral con-
traceptive use [2]; obesity [3] and hyperinsulinemia [4]
are probable factors increasing risks of developing breast
carcinoma. Although many individuals exposed to these
risk factors, breast cancer develops only in a small group
of exposed people, implying that genetic factors might
contribute to the carcinogenic mechanisms and complex
interactions between many genetic and environmental
factors might be the major cause of breast cancer.
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Previously, a number of studies indicate that family his-
tory is a risk factor for breast cancer [5], indicating the pos-
sible roles for genetic variations on the increased
susceptibility to breast cancer. Recent published meta-
analyses suggest that polymorphisms of Fok1 [6], XRCC1
codon 399[7] and methylenetetrahydrofolate reduct-
ase[8] might have a significant association with increased
breast cancer risk. Nevertheless, conversely, some meta-
analysis failed to suggest a marked association of
increased susceptibility to breast cancer with polymor-
phisms of some genes, such as Estrogen receptor alpha
[9], CYP1A1 [10] and base-excision repair pathway genes
[11].
Recently, a growing body of research has conducted on
the association of breast cancer risk with tumour suppres-
sors. TP53, one of the most extensive studied genes as a
tumor suppressor, has been thought to have a critical
function in cell cycle regulation. In case of its mutation,
this regulation could be lost, resulting in cell proliferation
without control and development of cancer. Previously,
TP53 mutation has been indicated to associate with risks
of a number of cancers such as lung cancer[12], breast
cancer [13] and colorectal cancer [14]. The loss of TP53
gene could damage its DNA-binding properties and tran-
scription factor function, thus leading to aberrant cell pro-
liferation. In human populations, the TP53 gene is
polymorphic at amino acid 72 of the protein that it
encodes.
Recently, much attention has been focused on possible
associations of TP53 polymorphisms and cancer risks. The
most informative polymorphism in TP53 gene is located
in exon 4 at codon 72, which encodes two distinct func-
tional allelic forms arginine (Arg) and proline (Pro)
because of a transversion G to C [15], resulting in different
biochemical and biological protein features. Conse-
quently, three distinct genotypes were created, namely,
homozygous for arginine (Arg/Arg), homozygous for pro-
line (Pro/Pro), and heterozygous (Arg/Pro). Previously,
Arg variant has been thought to increase susceptibility to
gastric cancer[16] and Arg homozygosity might contribute
to cervical cancer [17]. Nevertheless, Pro homozygosity
might have an association with lung [18] and hepotocel-
lular cancer [19] risk. The heterozygous genotype Arg/Pro
has been implicated as a risk factor for bladder cancer
[20].
In recent literature, inconclusive data regarding TP53
codon 72 were found in some cancers, such as gastric can-
cer in which controversial conclusions were obtained in
Asians [21] and in individuals from Northern Brazil [22].
Similarly, up to date, published data on the possible asso-
ciation of TP53 codon 72 polymorphism with breast car-
cinoma have also generated controversial and
inconclusive results. To the best of our knowledge,
whether TP53 codon 72 polymorphism could increase
breast cancer risk remains largely uncertain. To clarify this
association may help us better understand the possible
risk of breast cancer and therefore contribute to its preven-
tion.
As a single study may have been underpowered in clarify-
ing the relationship of TP53 codon 72 polymorphisms
with breast carcinoma susceptibility, in the present study
we performed evidence-based quantitative meta-analyses
that can increase statistical power to address the associa-
tion.
Materials and methods
Literature search strategy for identification of the studies
We carried out a search in the Medline, EMBASE, OVID,
Sciencedirect, and Chinese National Knowledge Infra-
structure (CNKI) without a language limitation, covering
all papers published up to Jan 2009, with a combination
of the following keywords: TP53, P53, codon 72, breast,
carcinoma, neoplasm, tumor, cancer and polymorphism. The
keywords were paired each time in order to get more rele-
vant information. For example, the word "breast" was
always kept and others were substituted in different
moments.
We evaluated potentially associated publications by
checking their titles and abstracts and then procured the
most relevant publications for a closer examination.
Moreover, the reference lists of the selected papers were
also screened for other potential articles that possibly
have been missed in the initial search. The following cri-
teria were used for the literature selection for the further
meta-analysis:
1. Studies concerning the association of TP53 codon 72
polymorphism with breast carcinoma;
2. Case–control or cohort studies;
3. Papers presenting the breast cancer diagnoses and the
sources of cases and controls;
4. Articles offering the size of the sample, odds ratios
(ORs) and their 95% confidence intervals (CIs) or the
information that can help infer the results;
5. The number of individuals homozygous for arginine
(Arg/Arg), proline (Pro/Pro) and heterozygous (Pro/Arg)
in breast cancer cases and controls should be offered;Journal of Experimental & Clinical Cancer Research 2009, 28:115 http://www.jeccr.com/content/28/1/115
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6. The methods of data collection and analysis should be
statistically acceptable.
Accordingly, the following exclusion criteria were also
used:
1. The design and the definition of the experiments were
obviously different from those of the selected papers.
2. The source of cases and controls and other essential
information were not offered;
3. The genetic distribution of the control group was incon-
sistent with Hardy-Weinberg equilibrium (HWE).
4. Reviews and duplicated publications.
After searching, we reviewed all papers in accordance with
the criteria defined above for further analysis.
Data extraction
Data were carefully extracted from all eligible publications
independently by two of the authors according to the
inclusion criteria mentioned above. For conflicting evalu-
ations, an agreement was reached following a discussion.
If a consensus could not be reached, another author was
consulted to resolve the dispute and then a final decision
was made by the majority of the votes. The extracted infor-
mation was entered into a database. For data not provided
in the main text, the relevant information was obtained by
contacting corresponding authors as possible as we could.
Statistical analysis
The odds ratio (OR) of TP53 codon 72 polymorphisms
and breast cancer risk was estimated for each study. The
pooled ORs were performed for additive model (Arg/Arg
vs Pro/Pro), dominant model (Arg/Arg+Arg/Pro versus
Pro/Pro) and recessive model (Arg/Arg versus Arg/
Pro+Pro/Pro), respectively. For detection of any possible
sample size biases, the OR and its 95% confidence interval
(CI) to each study was plotted against the number of par-
ticipants respectively. A Chi-square based Q statistic test
was performed to assess heterogeneity. If the result of the
heterogeneity test was P > 0.05, ORs were pooled accord-
ing to the fixed-effect model (Mantel-Haenszel), Other-
wise, the random-effect model (DerSimonian and laird)
was used. The significance of the pooled ORs was deter-
mined by Z-test. The HWE was assessed via Fisher's exact
test.
Publication bias was assessed by visual inspection of fun-
nel plots[23], in which the standard error of log (OR) of
each study was plotted against its log (OR). An asymmet-
ric plot indicates a possible publication bias. The symme-
try of the funnel plot was further evaluated by Egger's
linear regression test[24]. In addition, fail-safe number for
P = 0.05 (Nfs0.05) [25] for the evaluation of the reliability
of meta-analysis, defined as the number of negative
results that could reverse the significant findings, was also
used to estimate the robustness of the meta analysis. Sta-
tistical analysis was undertaken using the program Review
Manager 4.2 and SAS 8.1 software.
Results
Study characteristics
A total of 131 studies regarding TP53 codon 72 with
respect to breast cancer were searched and screened for
retrieval, of which 97 irrelevant studies were excluded.
Then, 9 studies [26-34] were excluded because each of
them did not contain a control group. Next, of the
remaining 25 studies, 2 studies[35,36] were excluded due
to their insufficient data and 1 study [37] owing to its
review characteristic. Afterwards, another 5 studies [38-
42] were excluded because the genetic distributions of the
control groups were not in agreement with HWE. Lastly,
17 case-control studies were selected (Figure 1). Of the all
included 17 studies, 16 were written in English [43-58]
and 1 [59] in Chinese.
We established a database according to the extracted
information from each article. The relevant information
was listed in Table 1. According to the lists, the first author
and the number and characteristics of cases and controls
for each study as well as other necessary information were
presented. As shown in Table 2, the distributions of TP53
codon 72 genotype of the included studies were also pre-
sented. The controls of the included studies were all in
accordance with HWE.
Test of heterogeneity
We analyzed the heterogeneity of Arg/Arg versus Pro/Pro
and dominant model (Arg/Arg+Arg/Pro versus Pro/Pro)
as well as recessive model (Arg/Arg versus Arg/Pro+Pro/
Pro). As shown in Table 3, the heterogeneity for the over-
all data was significant in each of the above three models
respectively because the P values were less than 0.05 for
Q-tests. Thus, random-effect models were utilized for the
meta-analyses.
Meta-analysis results
Table 3 lists the main results of the meta-analysis. No evi-
dence showed that individuals who carry Arg allele have
an increased or decreased risk of breast carcinoma com-
pared with those who carry Pro allele.
In the present study, a total of 17 studies were included.
Nevertheless, the study conducted by Weston et al. [44]
concerned both Caucasians and Africans. Thus, the dataJournal of Experimental & Clinical Cancer Research 2009, 28:115 http://www.jeccr.com/content/28/1/115
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were extracted respectively and further assessed by Rev-
man 4.2 software. Consequently, the following results
reported 18 studies.
As shown in Table 3, for Arg/Arg vs Pro/Pro, the data avail-
able for our meta-analysis were obtained from 18 case-
control studies of 7377 cases and 6450 controls, of which
6288 cases and 5112 controls had the Arg/Arg genotype
and 1089 cases and 1338 controls had the Pro/Pro geno-
type of the TP53 codon 72. The overall OR was 1.20 (95%
CI = 0.96–1.50) and the test for overall effect Z value was
1.58 (P > 0.05). For dominant model (Arg/Arg+Arg/Pro
versus Pro/Pro), the data available for our meta-analysis
were obtained from 18 case-control studies containing
12226 cases and 10782 controls, of which 11137 cases
and 9444 controls had the combined genotypes of Arg/
Arg and Arg/Pro, while 1089 cases and 1338 controls had
the homozygote Pro/Pro genotype. The overall OR was
1.12 (95% CI = 0.96–1.32) and the test for overall effect Z
value was 1.47 (P > 0.05). Similarly, for recessive model
(Arg/Arg versus Arg/Pro+Pro/Pro), the data were extracted
from the 18 case-control studies concerning 12226 cases
and 10782 controls, of which 6288 cases and 5112 con-
trols had the wild-type homozygote Arg/Arg genotype
while 5938 cases and 5670 controls had the combined
variant genotypes (Arg/Pro and Pro/Pro) of the TP53
codon 72. The overall OR was 1.13 (95% CI = 0.98–1.31)
and the test for overall effect Z value was 1.65 (P > 0.05).
Considering the possible impact of ethnic variation on the
results, we conducted subgroup analysis concerning
Asians, Caucasians and Africans, respectively. Likewise,
the subgroup analyses failed to suggest marked associa-
tion between TP53 codon 72 polymorphisms and breast
cancer risk in Asians, Caucasians and Africans.
Sensitivity analysis
In order to compare the difference and evaluate the sensi-
tivity of the meta-analyses, we also presented the results of
the fixed-effect models as listed in Table 3. In all, the
results were not significantly different between the two
models, suggesting the robustness of the meta-analyses.
Moreover, we also conducted one-way sensitivity analy-
sis[60] to evaluate the stability of the meta-analysis. The
statistical significance of the results was not altered when
any single study was omitted (data not shown), confirm-
ing the stability of the results. Hence, results of the sensi-
tivity analysis suggest that the data in this meta-analysis
are relatively stable and credible.
Bias diagnostics
Funnel plots were created for assessment of possible pub-
lication biases. Then, Egger's linear regression tests were
used to assess the symmetric of the plots. As shown in
Table 4, for the dominant model, the data suggest that the
funnel plot is symmetrical. However, for the additive and
recessive model, the results indicate possible asymmetric
of the funnel plots. Therefore, we further calculated the
Nfs0.05 for evaluation of the stability of the results. Conse-
quently, the Nfs0.05 were 237, 143 and 271 for additive,
dominant model and recessive model respectively, which
were more than five times of the number of the included
studies, suggesting that the results of these meta-analyses
are relatively stable and the publication biases might not
have an evident influence on the results of the meta-anal-
yses.
Discussion
In the present study, the results of meta-analyses showed
that individuals with TP53 codon 72 polymorphism
might not have significant associations with increased or
decreased susceptibility to breast carcinoma.
A previous meta-analysis conducted by Koushik et al. [61]
regarding cervical cancer suggests that homozygote Arg/
Arg genotype increases susceptibility to both squamous
cell carcinoma and adenocarcinoma. While another meta-
analysis [62] indicates that Arg/Arg genotype only associ-
ates with increased risk of cervical adenocarcinoma but
not squamous cell carcinoma. Then, Sousa et al. [63]
failed to demonstrate Arg/Arg genotype as a risk marker
for the development of cervical lesions in most of Euro-
pean countries. Conversely, nonassociations of TP53
codon 72 polymorphism with lung carcinoma [64] and
gastric cancer [65] risk were found by meta-analysis. Nev-
ertheless, An updated meta-analysis concerning lung can-
cer implied that Pro allele is a low-penetrant risk factor for
The flow diagram of included/excluded studies Figure 1
The flow diagram of included/excluded studies.Journal of Experimental & Clinical Cancer Research 2009, 28:115 http://www.jeccr.com/content/28/1/115
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developing lung cancer [66]. Thus, whether TP53 codon
72 polymorphism contributes to susceptibility to cancers
varies in different types of cancer. In the present study, no
evidence showed TP53 codon 72 polymorphism as a risk
factor for breast cancer.
The underlying mechanisms by which TP53 polymor-
phism influences cancer risk are not fully understood.
TP53 is the most frequently investigated gene that is often
mutated in a variety of cancers. Nevertheless, several sin-
gle-nucleotide polymorphisms have been studied and
reported in TP53 gene [67]. The polymorphism of TP53
codon 72 occurs in a proline-rich region that is thought to
play a critical role in the growth suppression and apop-
totic functions of TP53 protein [68]. The two polymor-
phic variants differ in their capability of binding the
transcriptional protein, activating transcription and sup-
pressing the transformation of some primary cells [69].
For example, Arg variant might induce cell apoptosis and
suppress transformation more efficiently than Pro variant
do, which may be due to the ability of the Arg variant to
localize in mitochondria that regulates the release of cyto-
chrome c into cytosol. However, the present meta-analysis
indicates that neither Arg nor Pro carriers may have a sig-
nificant association with breast cancer risk. It is likely that
TP53 codon 72 polymorphisms rarely affect the tumori-
genesis and progression of breast carcinoma. Considering
that the same polymorphism may play different roles in
cancer susceptibility among different ethnic populations
and the frequencies of single nucleotide polymorphisms
may be different ethnicity, we stratified the data by race
into three groups concerning Asians, Caucasians or Afri-
Table 1: Characteristics of studies included in the meta-analysis
First Author Publication 
Year
Number of 
Cases
Number of 
Controls
Types of Cases Type of controls Method Country Ref. No.
Själander 1996 212 689 Ductal 
carcinoma 
(>80% of the 
total cases)
Pooled individuals 
from several controls
PCR-RFLP Sweden 43
Weston 1997 81 147 NS NS AS-PCR USA 44
Li 2002 28 50 NS 50 healthy people 
(age-matched)
AS-PCR China 45
Wang-
Gohrke
2002 577 579 NS NS PCR-RFLP Germany 46
Buyru 2003 115 76 NS 76 healthy people PCR-RFLP Turkey 47
Huang 2003 200 282 NS 282 healthy people PCR-CTPP China 48
Katiyar 2003 77 41 77 Sporadic 
breast cancer
41 Normal healthy 
women (age-
matched)
PCR-RFLP India 49
Mabrouk 2003 30 49 NS NS PCR-RFLP Tunisia 50
Kalemi 2005 42 51 NS 51 healthy women PCR-RFLP UK 51
Tommiska 2005 1827 736 888 unselected 
breast cancer; 
939 familial 
breast cancer
736 healthy 
population
TaqMan Sweden 52
Baynes 2007 2023 2197 NS NS TaqMan UK 53
Gochhait 2007 576 243 243 sporadic 
breast cancer; 
333 unrelated 
breast cancer
243 healthy females 
(ethnically and 
geographically 
matched)
PCR-RFLP India 54
Khadang 2007 221 205 221 sporadic 
breast cancer
205 healthy blood 
donors
AS-PCR Iran 55
Schmidt 2007 5191 3834 NS NS TaqMan+ PCR-
RFLP
UK 56
Sprague 2007 1912 1527 1708 invasive 
breast cancer; 
204 in situ 
breast cancer
1527 drivers (< 65 
year) and roster of 
Medicare 
beneficiaries 
(65–74 year)
TaqMan USA 57
Zhang 2007 84 168 NS 168 healthy controls 
(geographic- and age-
matched)
PCR-RFLP China 59
Akkiprik 2008 95 107 NS 107 age-matched 
healthy controls
PCR-RFLP Turkey 58
AS-PCR: Allele Specific PCR; RFLP: restriction fragment length polymorphism; CTPP: confronting two-pair primers; NS: not specifiedJournal of Experimental & Clinical Cancer Research 2009, 28:115 http://www.jeccr.com/content/28/1/115
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cans, respectively. Ultimately, statistically similar results
were obtained, confirming nonassociation of TP53 codon
72 polymorphism with breast cancer risk.
A well-known risk factor, HPV infection, is thought to
have an association with increased susceptibility to some
cancers such as cervical [70] and oral cancer [71]. Evi-
dence suggests that P53Arg72 protein may be more sus-
ceptible than P53Pro72 protein to HPV mediated
degradation, thus increasing risk of HPV associated can-
cers [17]. Growing body of literature indicates HPV infec-
tion as a possible risk factor for breast cancer [72].
However, we did not further investigate the possible asso-
ciation of HPV infection with TP53 codon 72 polymor-
phism due to the insufficient data in the primary included
studies.
Heterogeneity is a potential problem when interpreting
the results of meta-analysis [73]. In the present study, sig-
nificant between-study heterogeneity existed in overall
comparisons. Nevertheless, when the data were stratified
by race, the heterogeneity was decreased or removed, sug-
gesting that differences of genetic backgrounds and the
environment existed among different ethnicities. In the
present meta-analysis, we excluded the studies in which
the control groups were deviate from HWE. Thus, the
between-study heterogeneity might be reduced. Moreo-
ver, random-effect models were used for combination of
the data. Accordingly, the results may be credible and sta-
ble although the heterogeneity seemed evident.
Some limitations might be included in this study. First, in
this meta-analysis, most published studies and papers
Table 2: Distribution of TP53 codon 72 genotype among breast cancer cases and controls included in the meta-analysis
First author Cases Controls HWE (control)
Arg/Arg Arg/Pro Pro/Pro Arg/Arg Arg/Pro Pro/Pro Chi-square P
Själander 24 93 95 61 253 375 3.681 0.055
Weston (Caucasian) 6 27 32 3 42 72 1.189 0.276
Weston (African) 6 9 1 12 14 4 0.001 0.979
Li 11 11 6 10 26 14 0.109 0.741
Wang-Gohrke 282 221 49 300 203 40 0.485 0.486
B u y r u 6 43 91 22 14 31 2 1 . 6 5 7 0 . 1 9 8
Huang 64 100 36 114 138 30 1.545 0.214
Katiyar 20 51 6 9 24 8 1.205 0.272
Mabrouk 18 9 3 19 26 4 1.432 0.231
Kalemi 26 13 3 10 32 9 3.326 0.068
Tommiska 825 617 109 403 278 52 0.183 0.669
Baynes 1107 768 148 1177 854 166 0.414 0.520
Gochhait 86 109 48 76 160 97 0.413 0.521
Khadang 83 109 29 75 90 40 1.873 0.171
Schmidt 2797 2008 386 2024 1523 287 0.001 0.983
Sprague 823 570 89 705 490 83 0.03 0.862
Zhang 21 45 17 47 87 33 0.406 0.524
Akkiprik 25 50 20 46 49 12 0.038 0.846
Table 3: Main results of the pooled data in the meta-analysis
No. of cases/
controls
Arg/Arg vs Pro/Pro (Arg/Arg+Arg/Pro) vs Pro/Pro Arg/Arg vs (Arg/Pro+Pro/Pro)
OR (95%CI) P P (Q-test) OR (95%CI) P P (Q-test) OR (95%CI) P P (Q-test)
Random-effect model
Total 12226/10782 1.20 (0.96–1.50) 0.11 0.000 1.12 (0.96–1.32) 0.14 0.01 1.13 (0.98–1.31) 0.10 0.000
Caucasian 11549/9830 1.15 (0.91–1.44) 0.24 0.001 1.11 (0.95–1.30) 0.17 0.06 1.09 (0.93–1.27) 0.28 0.000
Asian 631/873 1.36 (0.61–3.03) 0.45 0.000 1.19 (0.67–2.10) 0.55 0.006 1.22 (0.72–2.05) 0.46 0.002
African 46/79 1.46 (0.38–5.62) 0.58 0.76 1.12 (0.31–4.10) 0.86 0.45 1.60 (0.63–4.06) 0.32 0.22
Fixed-effect model
Total 12226/10782 1.09 (0.99–1.20) 0.10 0.000 1.09 (0.99–1.19) 0.06 0.01 1.04 (0.99–1.10) 0.13 0.000
Caucasian 11549/9830 1.07 (0.96–1.18) 0.24 0.001 1.08 (0.98–1.19) 0.12 0.06 1.03 (0.98–1.09) 0.25 0.000
Asian 631/873 1.27 (0.94–1.71) 0.12 0.000 1.16 (0.89–1.51) 0.26 0.006 1.15 (0.92–1.44) 0.22 0.002
African 46/79 1.47 (0.39–5.62) 0.57 0.76 1.17 (0.33–4.14) 0.80 0.45 1.67 (0.80–3.48) 0.17 0.22Journal of Experimental & Clinical Cancer Research 2009, 28:115 http://www.jeccr.com/content/28/1/115
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written in English or Chinese were searched. Moreover,
although papers written in some other languages, cited by
PubMed, were also searched, it is possible that some
related published or unpublished studies that might meet
the inclusion criteria were missed. Hence, some inevitable
publication biases might exist in the results, though the
Nfs0.05 showed no remarkable publication biases in the
meta-analyses. Second, in the subgroup analysis, the
number of studies regarding Africans was relatively lim-
ited. It may be underpowered to explore the real associa-
tion. Thus, the results may be interpreted with caution.
Third, whether the experimental and control groups were
from the same socio-economic status or the same geo-
graphic area have not been clearly presented in some of
the included original papers, leading to any possible
biases. Furthermore, the sample sizes of some included
studies are rather small, which might be one of the rea-
sons contributing to the between-study heterogeneity.
Therefore, a number of further studies with large sample
sizes with well-matched controls are required. Besides,
gene-gene and gene-environment interactions should also
be considered in the further studies.
In summary, despite the limitations, the results of the
present meta-analysis suggest that genetic variations of
TP53 codon 72 may not have a marked association with
breast cancer risk.
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